109 related articles for article (PubMed ID: 3529351)
1. Hydroxyproline/creatinine ratios as estimates of bone resorption in early postmenopausal women. Fasting and 24-h urine samples compared.
Pødenphant J; Riis BJ; Larsen NE; Christiansen C
Scand J Clin Lab Invest; 1986 Sep; 46(5):459-63. PubMed ID: 3529351
[TBL] [Abstract][Full Text] [Related]
2. The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis.
Riis BJ; Rødbro P; Christiansen C
Calcif Tissue Int; 1986 Jun; 38(6):318-22. PubMed ID: 3089552
[TBL] [Abstract][Full Text] [Related]
3. Effect of salt restriction on urine hydroxyproline excretion in postmenopausal women.
Need AG; Morris HA; Cleghorn DB; De Nichilo D; Horowitz M; Nordin BE
Arch Intern Med; 1991 Apr; 151(4):757-9. PubMed ID: 2012460
[TBL] [Abstract][Full Text] [Related]
4. Measurement of the fasting urinary hydroxyproline: creatinine ratio in normal adults and its variation with age and sex.
Hodgkinson A; Thompson T
J Clin Pathol; 1982 Aug; 35(8):807-11. PubMed ID: 7107952
[TBL] [Abstract][Full Text] [Related]
5. Biochemical markers of bone turnover in rheumatoid arthritis. Relation to anti-inflammatory treatment, sex, and menopause.
Als OS; Riis BJ; Gotfredsen A; Christiansen C; Deftos LJ
Acta Med Scand; 1986; 219(2):209-13. PubMed ID: 3485890
[TBL] [Abstract][Full Text] [Related]
6. Fasting urinary sodium/creatinine in relation to calcium/creatinine and hydroxyproline/creatinine in a general population of women.
Goulding A
N Z Med J; 1981 May; 93(683):294-7. PubMed ID: 6942284
[TBL] [Abstract][Full Text] [Related]
7. Minimal levels of serum estradiol prevent postmenopausal bone loss.
Reginster JY; Sarlet N; Deroisy R; Albert A; Gaspard U; Franchimont P
Calcif Tissue Int; 1992 Nov; 51(5):340-3. PubMed ID: 1458336
[TBL] [Abstract][Full Text] [Related]
8. Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis.
Christiansen C; Riis BJ; Nilas L; Rødbro P; Deftos L
Lancet; 1985 Oct; 2(8459):800-1. PubMed ID: 2864532
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women.
Christiansen C; Christensen MS; Larsen NE; Transbøl IB
J Clin Endocrinol Metab; 1982 Dec; 55(6):1124-30. PubMed ID: 7130340
[TBL] [Abstract][Full Text] [Related]
10. [Effects of hormone replacement therapy in bone resorption, in post-menopausal women].
Villaseca P; Arteaga E; Campusano C; López JM; Rojas A; Nazar G; O'Brien A
Rev Med Chil; 1996 Dec; 124(12):1439-46. PubMed ID: 9334477
[TBL] [Abstract][Full Text] [Related]
11. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.
Uebelhart D; Schlemmer A; Johansen JS; Gineyts E; Christiansen C; Delmas PD
J Clin Endocrinol Metab; 1991 Feb; 72(2):367-73. PubMed ID: 1991806
[TBL] [Abstract][Full Text] [Related]
12. Effect of estrogen (Premarin) replacement therapy on serum level of total estrogen and urinary excretion of calcium and hydroxyproline in postmenopausal Chinese women.
Ouyang PC; Chow SN; Huang SC; Hsieh CY
Proc Natl Sci Counc Repub China B; 1986 Jul; 10(3):162-6. PubMed ID: 3022320
[TBL] [Abstract][Full Text] [Related]
13. Effect of 1,25-dihydroxyvitamin D3 on biochemical indices of bone turnover in postmenopausal women.
Tjellesen L; Christiansen C; Rødbro P
Acta Med Scand; 1984; 215(5):411-5. PubMed ID: 6547563
[TBL] [Abstract][Full Text] [Related]
14. Bone mass as referent for urinary hydroxyproline excretion: age and sex-related changes in 125 normals and in primary hyperparathyroidism.
Hyldstrup L; McNair P; Jensen GF; Nielsen HR; Transbøl I
Calcif Tissue Int; 1984 Dec; 36(6):639-44. PubMed ID: 6442199
[TBL] [Abstract][Full Text] [Related]
15. Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.
Christiansen C; Christensen MS; Rødbro P; Hagen C; Transbøl I
Eur J Clin Invest; 1981 Aug; 11(4):305-9. PubMed ID: 6795047
[TBL] [Abstract][Full Text] [Related]
16. Serum alkaline phosphatase during hormone treatment in early postmenopausal women. A model for establishing optimal prophylaxis and treatment in postmenopausal osteoporosis.
Christiansen C; Rødbro P; Tjellesen L
Acta Med Scand; 1984; 216(1):11-7. PubMed ID: 6385631
[TBL] [Abstract][Full Text] [Related]
17. The effect of calcium supplements on plasma alkaline phosphatase and urinary hydroxyproline in postmenopausal women.
Horowitz M; Need AG; Philcox JC; Nordin BE
Horm Metab Res; 1985 Jun; 17(6):311-2. PubMed ID: 4018720
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women.
Lindsay R; Hart DM; Purdie D; Ferguson MM; Clark AS; Kraszewski A
Clin Sci Mol Med; 1978 Feb; 54(2):193-5. PubMed ID: 340117
[TBL] [Abstract][Full Text] [Related]
19. [Fasting urinary excretion of calcium, phosphorus and hydroxyproline in relation to creatinine. Normal values and correlations with 24-hour urine values (author's transl)].
Sebert JL; Cornaille G; San Juan MP; Kha TD; Blotman F; Simon L
Nouv Presse Med; 1981 Sep; 10(34):2799-801. PubMed ID: 7312590
[TBL] [Abstract][Full Text] [Related]
20. Bone loss during oestriol therapy in postmenopausal women.
Lindsay R; Hart DM; Maclean A; Garwood J; Clark AC; Kraszewski A
Maturitas; 1979 Jun; 1(4):279-85. PubMed ID: 399316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
